MMED Healthcare

MiniMed Group, Inc.

$18.85-0.26%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States
Market cap: 5.3B USD
Enterprise value: 5.3B USD
Full-time employees: 8,000

Overall health

Strength: growing faster than most peersgrowing faster than peers
Drawback: less profitable than most peersless profitable than peers
About average: valuation and risk (debt, liquidity and share-price swings)valuation and risk

Ranks #625 of 1,157 healthcare companies (bottom 47%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 58% of peers on operating cash profit (EBITDA), but only 0% on earnings.Cheaper than 58% of peers on operating cash profit, but only 0% on earnings.
Relative to its operating cash profit (EBITDA), MiniMed looks cheaper than 58% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, MiniMed looks cheaper than 58% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to July 2026.
MiniMed reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

50/ 100

Oct 5 51 → Nov 4 50 (-1)

Valuation

Is the price right?

45/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Held back by:

▼ Earnings yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-5.9%

SEC filings · 12 months to Jul 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield5.4%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsReported value50% base weight · Z-score 0.34Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-6.0%

SEC filings · 12 months to Jul 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield68.3%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

66/100

Moderate

2/3 inputs reported · Partial data

Since last quarter: ▲ Stronger

12-month revenue up 3.9%

Why

Stronger than most peers on:

▲ Revenue growth
▲ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0976 · MAD: 0.2991

3-year revenue growth11.4%

Yahoo Finance fallback · SEC figure unavailable or out of date · 3 fiscal years to Apr 2026Reported value33% base weight · Z-score 0.66Sector median: 0.0584 · MAD: 0.0840

Revenue growth14.3%

Yahoo Finance fallback · SEC figure unavailable or out of date · fiscal year to Apr 2026Reported value33% base weight · Z-score 0.84Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

31/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROA
▼ Operating margin
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-5.3%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score -1.02Sector median: 0.0706 · MAD: 0.1217

Return on assets-6.7%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score -1.55Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-4.0%

SEC filings · 12 months to Jul 2026Reported value33% base weight · Z-score -0.87Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin53.9%

SEC filings · 12 months to Jul 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-8.7%

SEC filings · 12 months to Jul 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Mixed versus peers:

▲ Debt / equity
▼ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

BetaUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.6250 · MAD: 0.3380

Current ratio1.81×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.56Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.02×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 1.01Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about MiniMed

Is MiniMed getting weaker?: Its latest SEC filing (Sep 14, 2026) showed no major changes. Its overall score is unchanged at 50/100 since Oct 28, 2026.
How is MiniMed valued vs its peers?: Priced about in line with its peers. Valuation scores 45/100 against 1,393 healthcare peers. Earnings yield -5.9% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -5.9% vs peers 1.5% (weaker than 100% of peers).
Is MiniMed growing?: Yes, faster than most of its peers. Growth scores 66/100 against 1,393 healthcare peers. Revenue growth 14.3% vs a peer median of 6.1% (stronger than 70% of peers).Revenue growth 14.3% vs peers 6.1% (stronger than 70% of peers).
How profitable is MiniMed?: Less profitable than most of its peers. Profitability scores 31/100 against 1,393 healthcare peers. Return on assets -6.7% vs a peer median of 1.7% (weaker than 72% of peers).Return on assets -6.7% vs peers 1.7% (weaker than 72% of peers).
How risky is MiniMed?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.02× vs a peer median of 0.22× (stronger than 86% of peers).Debt / equity 0.02× vs peers 0.22× (stronger than 86% of peers). Current ratio 1.81× vs a peer median of 2.59× (weaker than 64% of peers).Current ratio 1.81× vs peers 2.59× (weaker than 64% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jul 31, 2026 · filed Sep 14, 2026 · compared with the quarter ended Apr 24, 2026

No major changes

	Previous quarter	Latest quarter	Change
Revenue (12 months)	3.1B USD	3.2B USD	+3.9%
Net income (12 months)	−333.0M USD	−314.0M USD	−5.7%
Operating margin	-6.1%	-5.3%	+0.8 pts
Free cash flow (12 months)	−420.0M USD	−316.0M USD	−24.8%
Cash	298.0M USD	207.0M USD	−30.5%
Shares outstanding	280.8M	281.3M	+0.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Instruments & Supplies · 25 companies

Valuations in Medical Instruments & Supplies are near the bottom of their range since Jul 2018.

18% of months since Jul 2018 were valued lower than now.
0% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +17% vs the whole market, against a usual +86%.

Jul 2018Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY Apr 2024	FY Apr 2025	FY Apr 2026	Change
Gross margin	58.2%	56.3%	54.2%	▼ 2.1 pts
Operating margin	-2.8%	-5.4%	-6.1%	▼ 0.7 pts
Net margin	-4.5%	-7.8%	-10.7%	▼ 2.9 pts
Return on assets (ROA)	—	-5.1%	-7.2%	▼ 2.1 pts
Return on equity (ROE)	-3.2%	-6.4%	-9.2%	▼ 2.8 pts
Free cash flow margin	-4.3%	-2.0%	-13.5%	▼ 12 pts
Current ratio	—	1.32×	1.92×	▲ 45%
Quick ratio	—	0.88×	1.43×	▲ 62%

MMED price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Drawback: less profitable than most peersless profitable than peers

About average: valuation and risk (debt, liquidity and share-price swings)valuation and risk

Ranks #625 of 1,157 healthcare companies (bottom 47%)

See how it ranks against its peers

Worth knowing

Valuation signals disagree. Cheaper than 58% of peers on operating cash profit (EBITDA), but only 0% on earnings.Cheaper than 58% of peers on operating cash profit, but only 0% on earnings.

Relative to its operating cash profit (EBITDA), MiniMed looks cheaper than 58% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.Relative to its operating cash profit, MiniMed looks cheaper than 58% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to July 2026.

MiniMed reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about MiniMed

Is MiniMed getting weaker?

Its latest SEC filing (Sep 14, 2026) showed no major changes. Its overall score is unchanged at 50/100 since Oct 28, 2026.

How is MiniMed valued vs its peers?

Priced about in line with its peers. Valuation scores 45/100 against 1,393 healthcare peers. Earnings yield -5.9% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -5.9% vs peers 1.5% (weaker than 100% of peers).

Is MiniMed growing?

Yes, faster than most of its peers. Growth scores 66/100 against 1,393 healthcare peers. Revenue growth 14.3% vs a peer median of 6.1% (stronger than 70% of peers).Revenue growth 14.3% vs peers 6.1% (stronger than 70% of peers).

How profitable is MiniMed?

Less profitable than most of its peers. Profitability scores 31/100 against 1,393 healthcare peers. Return on assets -6.7% vs a peer median of 1.7% (weaker than 72% of peers).Return on assets -6.7% vs peers 1.7% (weaker than 72% of peers).

How risky is MiniMed?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.02× vs a peer median of 0.22× (stronger than 86% of peers).Debt / equity 0.02× vs peers 0.22× (stronger than 86% of peers). Current ratio 1.81× vs a peer median of 2.59× (weaker than 64% of peers).Current ratio 1.81× vs peers 2.59× (weaker than 64% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

3.1B USD

3.2B USD

+3.9%

Net income (12 months)

−333.0M USD

−314.0M USD

−5.7%

Operating margin

-6.1%

-5.3%

+0.8 pts

Free cash flow (12 months)

−420.0M USD

−316.0M USD

−24.8%

Cash

298.0M USD

207.0M USD

−30.5%

Shares outstanding

280.8M

281.3M

+0.2%

Key ratios

FY Apr 2024

FY Apr 2025

FY Apr 2026

Change

Gross margin

58.2%

56.3%

54.2%

▼ 2.1 pts

Operating margin

-2.8%

-5.4%

-6.1%

▼ 0.7 pts

Net margin

-4.5%

-7.8%

-10.7%

▼ 2.9 pts

Return on assets (ROA)

—

-5.1%

-7.2%

▼ 2.1 pts

Return on equity (ROE)

-3.2%

-6.4%

-9.2%

▼ 2.8 pts

Free cash flow margin

-4.3%

-2.0%

-13.5%

▼ 12 pts

Current ratio

—

1.32×

1.92×

▲ 45%

Quick ratio

—

0.88×

1.43×

▲ 62%